Increased serum neopterin concentrations in patients with Alzheimer's disease
- PMID: 10369114
- DOI: 10.1515/CCLM.1999.070
Increased serum neopterin concentrations in patients with Alzheimer's disease
Abstract
We measured serum neopterin concentrations in 24 patients with Alzheimer's disease (8 males, 16 females; age: 73.1+/-6.2 years; free of any infectious process) and fourteen controls of similar age (4 males, 10 females; age: 69.7+/-8.8 years). Compared to controls, significantly higher concentrations of neopterin (p< 0.01) were found in patients with Alzheimer's disease. Among patients, concentrations of neopterin were higher in those with lower mini-mental-state (p < 0.05), and an inverse correlation existed between mini-mental-state and neopterin concentrations. No such association existed with the duration of the disease. There were also significant correlations between neopterin and serum concentrations of immune activation markers such as soluble tumor necrosis factor (TNF) receptor and soluble interleukin-2 receptor (all p<0.01). Thus, increased concentrations of neopterin in serum of patients with Alzheimer's disease correlate with the severity of dementia. The data imply a chronic state of peripheral immune activation in Alzheimer's disease.
Similar articles
-
No relationship between lipoprotein-associated phospholipase A2, proinflammatory cytokines, and neopterin in Alzheimer's disease.Exp Gerontol. 2016 May;77:1-6. doi: 10.1016/j.exger.2016.01.014. Epub 2016 Jan 29. Exp Gerontol. 2016. PMID: 26828804
-
Immune activation in patients with Alzheimer's disease is associated with high serum phenylalanine concentrations.J Neurol Sci. 2013 Jun 15;329(1-2):29-33. doi: 10.1016/j.jns.2013.03.007. Epub 2013 Apr 6. J Neurol Sci. 2013. PMID: 23566485
-
Tryptophan degradation and immune activation in Alzheimer's disease.J Neural Transm (Vienna). 2000;107(3):343-53. doi: 10.1007/s007020050029. J Neural Transm (Vienna). 2000. PMID: 10821443
-
A systematic review and meta-analysis of pteridines in mild cognitive impairment and Alzheimer's disease.BMC Geriatr. 2025 Feb 13;25(1):94. doi: 10.1186/s12877-025-05760-9. BMC Geriatr. 2025. PMID: 39948480 Free PMC article.
-
On the Possible Relevance of Bottom-up Pathways in the Pathogenesis of Alzheimer's Disease.Curr Top Med Chem. 2020;20(15):1415-1421. doi: 10.2174/1568026620666200514090359. Curr Top Med Chem. 2020. PMID: 32407280 Review.
Cited by
-
Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry.Curr Neuropharmacol. 2021;19(5):591-609. doi: 10.2174/1570159X18666200729103529. Curr Neuropharmacol. 2021. PMID: 32744952 Free PMC article. Review.
-
Probiotic Supplementation in Patients with Alzheimer's Dementia - An Explorative Intervention Study.Curr Alzheimer Res. 2018;15(12):1106-1113. doi: 10.2174/1389200219666180813144834. Curr Alzheimer Res. 2018. PMID: 30101706 Free PMC article.
-
Can peripheral leukocytes be used as Alzheimer's disease biomarkers?Expert Rev Neurother. 2009 Nov;9(11):1623-33. doi: 10.1586/ern.09.118. Expert Rev Neurother. 2009. PMID: 19903022 Free PMC article. Review.
-
Serum levels of the immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of body fat.J Gerontol A Biol Sci Med Sci. 2010 Aug;65(8):858-65. doi: 10.1093/gerona/glq066. Epub 2010 May 17. J Gerontol A Biol Sci Med Sci. 2010. PMID: 20478905 Free PMC article.
-
Inflammaging as a prodrome to Alzheimer's disease.J Neuroinflammation. 2008 Nov 11;5:51. doi: 10.1186/1742-2094-5-51. J Neuroinflammation. 2008. PMID: 19014446 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical